Adamantinoma — Clinical Trials

MONDO:00024224 active·3 recruitingLast updated: Mar 18, 2026, 11:39 PM

Trial Landscape

Adamantinoma has an emerging clinical trial program, driven by drug treatment.

Recruiting

Active Trials

By Approach

Drug Treatment4

By Phase

Early Phase 1

Phase 1

Phase 2

Sponsor Types

Academic/Other3Industry1

Top Sponsors

Parabilis Medicines, Inc.

Trial Locations

United States4 trials

Australia2 trials

Canada2 trials

Trials often recruit across multiple countries, so totals exceed the trial count.

4 Trials

Phase 2Recruiting

NCT05233397

ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma

Sponsor:Nationwide Children's Hospital

United StatesStarted: Dec 2022Est. completion: Dec 2029Updated: Mar 2026

Phase 2Recruiting

NCT05286788

MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma

Sponsor:Nationwide Children's Hospital

United StatesStarted: Apr 2023Est. completion: Apr 2027Updated: Jan 2026

Phase 1Recruiting

NCT05919264

FOG-001 in Locally Advanced or Metastatic Solid Tumors

Sponsor:Parabilis Medicines, Inc.

United StatesStarted: May 2023Est. completion: Aug 2027Updated: Feb 2026

Early Phase 1Active, Not Recruiting

NCT03970226

Tocilizumab in Children With ACP

Sponsor:University of Colorado, Denver

United StatesStarted: Sep 2019Est. completion: May 2027Updated: Feb 2026

Stay informed about clinical trials for Adamantinoma.

Follow this disease to get updates when trials open, close, or change status.

Follow This Disease — Free

Already have an account? Sign in to manage your watchlists.

Data sourced from ClinicalTrials.gov via Kisho's automated pipeline. Trials refreshed every 4 hours for monitored diseases.

Last sync: March 18, 2026 at 11:39 PM